9905270-6
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 213/75, A61K 31/44 — A1

(11) International Publication Number: **WO 98/54143**

(43) International Publication Date: 3 December 1998 (03.12.98)

(21) International Application Number: PCT/DK98/00195

(22) International Filing Date: 15 May 1998 (15.05.98)

(30) Priority Data:
9711119.9 29 May 1997 (29.05.97) GB

(71) Applicant *(for all designated States except US)*: LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) [DK/DK]; Industriparken 55, DK–2750 Ballerup (DK).


(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: OTTOSEN, Erik, Rytter [DK/DK]; Lotusvej 6, DK–3650 Ølstykke (DK).

(74) Common Representative: LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB); Patent Dept., Kristensen, Per, Rydahl, Industriparken 55, DK–2750 Ballerup (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS



(I)

(57) Abstract

The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3– or 4–position, in which formula R_1 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C_1–C_4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C_9–C_{20} divalent hydrocarbon radical which can be saturated, straight or branched or Q stands for C_4–C_{20} divalent hydrocarbon radical which can be cyclic or unsaturated and X stands for oxygen, sulfur or nitrogen the latter optionally being substituted by hydrogen or C_1–C_4 alkyl and R_2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C_1–C_4 alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, cyano, carboxamido, sulfamoyl or nitro; and pharmaceutically acceptable, non–toxic salts and N–oxides thereof. The present compounds are of value in the human and veterinary practice.